Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators may attenuate PCSK9induced low-density lipoprotein receptor (LDLR) degradation in lysosome and promote the clearance of circulating low-density lipoprotein cholesterol (LDL-C). A novel series of tetrahydroprotoberberine derivatives (THPBs) were designed, synthesized, and evaluated as PCSK9 modulators for the treatment of hyperlipidemia. Among them, eight compounds exhibited excellent activities in downregulating
cholesterol;
Lipid-lowering; PCSK9 expression; Low-density lipoprotein receptor; Total cholesterol; Hyperlipidemia hamster hepatic PCSK9 expression better than berberine in HepG2 cells. In addition, five compounds 15, 18, 22, (R)-22, and (S)-22 showed better performance in the low-density lipoprotein, labeled with 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethyl-indocarbocyanine perchlorate (DiI-LDL) uptake assay, compared with berberine at the same concentration. Compound 22, selected for in vivo evaluation, demonstrated significant reductions of total cholesterol (TC) and LDL-C in hyperlipidemic hamsters with a good pharmacokinetic profile. Further exploring of the lipid-lowering mechanism showed that compound 22 promoted hepatic LDLR expression in a dose-dependent manner in HepG2 cells. Additional results of human ether-a`go-go related gene (hERG) inhibition assay indicated the potential druggability for compound 22, which is a promising lead compound for the development of PCSK9 modulator for the treatment of hyperlipidemia. 
Introduction
Cardiovascular diseases (CVDs) are a major cause of death throughout the world 1 . Elevation of circulating low-density lipoprotein cholesterol (LDL-C) leads to an increased incidence of cardiovascular diseases 2 . Proprotein convertase subtilisin/kexin type 9 (PCSK9), which originally found in patients with autosomal dominant hypercholesterolemia (ADH), could adjust the circulating LDL-C levels via inducing low-density lipoprotein receptor (LDLR) endocytosis and lysosomal degradation in hepatic cell 3, 4 . Loss-of-function mutations in PCSK9 in humans perform significantly lower LDL-C levels and CVDs morbidity 5 , which indicates that PCSK9 may act as a therapeutic target for LDL-C-lowering.
Owing to the promise of its therapeutic potential, multiple PCSK9 monoclonal antibodies (mAbs) have been evaluated in clinical trials. Among them, two PCSK9 mAbs (alirocumab and evolocumab), have been approved by food and drug administration (FDA) for the treatment of coronary heart disease (CHD) 6, 7 . In addition, a small interfering RNA ALN-PCSSC, which inhibited the synthesis of PCSK9 also demonstrated lower LDL-C levels in patients administered in phase 3 clinical trial 8 . However, both of these therapeutic drugs need to be administered by injection and costly, which may restrict their clinical promotion. Therefore, an orally available small molecule targets PCSK9 would be a highly desirable alternative therapeutic agent, based on its ease of administration and lower cost.
Small molecules target PCSK9 have been identified (Fig. 1 ). Compound 1 decreased PCSK9 protein expression in HepG2 cells with the IC 50 value of 29.7 nmol/L 9 . Compound 2 (PF-06446846) developed by Pfizer reduced secreted PCSK9 level with the IC 50 value of 0.5 mmol/L 10e13 . Natural products, such as moracin C (3), adenosine (4) , and manglisin E (5), also exhibited potent down-regulation on PCSK9 mRNA expression in HepG2 cells, with IC 50 values of 16.8, 18 .46, and 3.15 mmol/L, respectively 14e16 .
Berberine (BBR, 6, Fig. 1 ), the main bioactive ingredient of Coptis chinensis, reduced serum total cholesterol (TC) by 29% and LDL-C by 25% in 32 hypercholesterolemic patients after 3 months of treatment 17 . It was also identified reducing PCSK9 protein expression in HepG2 cells 18 , and decreasing PCSK9 mRNA level with the IC 50 value of 8.04 mmol/L 15 . However, there are some factors that limit its wide prescription, such as its high oral dose of 1.0e1.5 g/day, poor bioavailability (F<1%) and high hERG channel inhibitory activity (IC 50 Z 3.1 mmol/L) 17,19e24 . Therefore, with the rapid rise in the number of patients with hyperlipidemia worldwide, discovering novel therapeutics to treat hyperlipidemia with better efficacy and fewer side effects has been a research focus in academia and industry.
It is known that tetrahydroprotoberberine deviratives (THPBs), which are the primary components of natural isoquinoline alkaloids, also exhibit a wide range of bioactivities 25e27 . Our group is dedicated to performing chemical modification of THPBs and constructing a library of small molecules with different scaffolds 28e33 . Herein, we described a novel series of indolecontaining THPB derivatives with anti-hyperlipidemia activity. We screened our in-house THPB library through PCSK9 expression in HepG2 cells. Fortunately, compound 7 featuring a novel scaffold, down-regulating PCSK9 expression assay at 5 mmol/L. In this study, based on the core structure of hit compound 7, a series of novel indole-containing THPBs as PCSK9 modulators were designed and synthesized, as well as the detailed structureeactivity relationship (SAR) analysis, in vitro and in vivo biological evaluation, and pharmacokinetic studies.
Results and discussion

Chemistry
In order to obtain novel compounds to reduce the PCSK9 expression in HepG2 cells, we screened our in-house THPB library, and compound 7 showed biological activity (PCSK9 protein level 0.84 @5 mmol/L). To improve the potency, a series of novel indole-containing THPBs were designed based on the hit compound 7 (Scheme 1). Firstly, the oxacyclopentene of ring A was opened, we introduced various alkoxy groups at the 2-and 3position on the ring A and maintained the ring D, and novel compounds 8-13 were designed. Then, in order to reduce the potential hERG channel inhibition and improve the bioavailability, by introducing the methoxyl group at the 12-position of the ring D and investigating different substituents on the ring A, novel compounds 14-26 were designed. In addition, chiral compounds (R)-and (S)-22 were also synthesized to explore the influence of the molecular configuration. Finally, introduction of the chlorine and bromine at the 13-position of the ring D, we obtained compounds 27 and 28.
On the basis of the above design, indole-containing THPBs (7-28) were synthesized through the route shown in Scheme 1. The procedures of Henry reaction was used to obtain the corresponding nitrostyrene 30. Reduction of the resulting nitrostyrenes with LiAlH 4 produced the phenylethanamine intermediate 31. Then, phenylethanamine 31 and the substituted indole-3-acetic acid 32 were employed to generate amide 33, which was further cyclized under the presence of phosphoryl trichloride (POCl 3 ) to give imine 34 in excellent yields, according to the procedures of the BischlereNapieralski reaction. Reduction of the resulting imine 34 with sodium borohydride produced the key amine intermediate 35. Cyclization of amine 35 via the PictecteSpengler reaction with formaldehyde resulted in the target products 7-28 (Scheme 2).
Additionally, chiral compounds (R)-and (S)-22 were prepared according to the procedure outlined in Scheme 3. Asymmetric hydrogenation of imine 35p, catalyzed by a chiral Ru(II) complex (Noyori's catalyst) 34e36 produced chiral amines (R)-35p, and (S)-35p, followed by cyclization with formaldehyde to give (R)-and (S)-22.
Structureeactivity relationship of indole-containing THPBs
The human hepatoma cell line HepG2 cells were used to investigate the PCSK9 expression. All indole-containing THPBs were screened to examine their ability to down-regulate PCSK9 expression in HepG2 cells. Structures of the indole-containing THPBs (compounds 7-28) and their regulatory activity on PCSK9 protein expression are shown in Table 1 (data of PCSK9 protein level is expressed as a mean of the fold of vehicle). Initial screening was carried out of each compound at a concentration of 5 mmol/L using Western blot assay (Supporting Information Fig. S1 ).
The SAR study was first focused on the effect of the side chains at the 2-and 3-position of the aromatic ring A (Table 1) . The oxacyclopentene was opened, and a methoxyl or substitutedbenzyloxy group was attached at the 2-and 3-position of the compound 7. The obtained compounds 8 and 13 showed higher activity on the down-regulation of PCSK9 expression than berberine and hit compound 7 (0.68 and 0.69 vs. 0.71 and 0.84, respectively). Compounds 9-12 bearing 2-F-OBn, 3-F-OBn, 4-F-OBn, or 3-Me-OBn at the 2-position, respectively, reduced their activities on the down-regulation of PCSK9 (1.33, 0.82, 0.81, and 0.93).
Next, on the indole ring D of compound 7, the hydrogen atom at the 12-position was replaced with electron-donating methoxyl group. Compound 14 exhibited the similar biological activity with compound 7 (0.86 vs. 0.84). Then, retaining the methoxyl group at the 2-position, different substituted-benzyloxy group was introduced at the 3-position of the ring A. Compounds 15 and 18 displayed better biological activity than berberine on the downregulation of PCSK9 (0.50 and 0.56 vs. 0.71). Replacement the substituted benzyloxy group to the trifluoroethoxyl group, compound 21 also exhibited good activity in down-regulating PCSK9 expression (0.58). Introduction of different substituted-benzyloxy group at the 2-position, compounds 22-26 were obtained. Compound 22 displayed significant down-regulation of PCSK9 expression (0.24), which is much better than berberine. Therefore, we also synthesized the chiral compounds (R)-and (S)-22, and further evaluated their biological activities on the down-regulation of PCSK9. The R-configured enantiomer (R)-22 was more effective than the S-configured compound (S)-22 (0.21 vs. 0.51).
Scheme 1 Design of indole-containing THPBs. Finally, by replacing the hydrogen to the chlorine and bromine at the 13-position, compounds 27 and 28 reduced their activities on the down-regulation of PCSK9 (0.86 and 0.97). We concluded that the methoxyl group at the 12-position played a significant role in down-regulating PCSK9 expression.
DiI-LDL uptake assays
Whether down-regulation of PCSK9 expression could promote LDL-C clearance in hepatic cells was determined by low-density lipoprotein, labeled with 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiI-LDL) uptake assay as previously described 20 . Eight compounds 8, 15, 18, 21, 22, (R)-22, (S)-22, and 24 which exhibited better activity in decreasing hepatic cell PCSK9 expression than berberine, were co-incubated with HepG2 cells for the LDL-uptake assay. The results are summarized in Table 2 . Firstly, berberine showed its LDL uptake rates with 1.38, compared to vehicle (DMSO). Subsequently, the above eight biological active compounds 8, 15, 18, 21, 22, (R)-22, (S)-22, and 24 were tested, and among them, five compounds 15, 18, 22, (R)-22 and (S)-22 displayed good LDL uptake rate (1.83, 1.78, 2.37, 2.19, and 1.83, respectively), which is much better than berberine (LDL uptake rate 1.38). The racemate 22 showed was slightly more potent than these two enantiomers (R)-and (S)-22, so the racemate 22 were used in the pharmacokinetic evaluation and in vivo biological assay. All selected compounds (<20 mmol/L) tested here showed no significant cytotoxicity in HepG2 cells (Supporting Information Table S1).
Selectivity evaluation
As a natural product, berberine and its derivatives exhibited various biological activities, including anti-depressant, anti-diabetes, and anti-inflammatory effects. Six compounds (8, 15, 18, 21, 22 , and 24) which exhibited better activity in decreasing hepatic cell PCSK9 expression than berberine, were selected to evaluate the biological selectivity, such as b 1 adrenergic receptor antagonist activity, dopamine D 1 and D 2 antagonist activity, and antagonistic activity on the serotonin 5-HT 1B ( Table 3) . Among them, compound 22 exhibited good selectivity against b 1 adrenergic receptor, dopamine D 1 and D 2 receptor (IC 50 ! 100 mmol/L). Compound 22 showed moderate antagonistic activity on the serotonin 5-HT 1B (IC 50 Z 13.43 mmol/L). The selectivity of compound 22 is better than berberine 21 .
Preliminary pharmacokinetic (PK) evaluation of compound 22
To explore the further druggability of the new identified indolecontaining THPB derivatives, compound 22 was further evaluated for its pharmacokinetic properties in hamsters after oral administration and intravenous, respectively. As shown in Table 4 , compound 22 given orally at 20 mg/kg displayed a half-life (t 1/2 ) of 6.35 h, the maximum plasma concentration (C max ) of 169 ng/mL, and an AUC 0--N value of 1005 ng/mL$h. Besides, compound 22 showed an oral bioavailability of 21.9%. Taken together, compared to the poor PK of the natural product berberine with low oral bioavailability (w0%) 22, 23 , compound 22 exhibited significant improvements on overall PK properties.
Oral efficacy evaluation of compound 22 in hyperlipidemic hamsters in vivo
In order to verify the hypolipidemic effect of compound 22 in vivo, high-fat diet (HFD)-induced hyperlipidemic hamster model was employed. Fenofibrate was used as the positive control during the in vivo studies 37 . After 21 days treatment, compared to the HFD control group, HFD hamsters given compound 22 30 mg/kg by oral gavage showed 36.7% reduction in serum TC ( Fig. 2A ) and 41.4% reduction in serum LDL-C, respectively ( Fig. 2B ), which confirmed the hypolipidemic effect of compound 22 in vivo. The efficacy data showed that fenofibrate (p.o., 100 mg/kg) decreased TC and LDL-C in 71.3% and 79.4%, respectively, compared to hamsters in the HFD control group.
Also, serum TC and LDL-C in the HFD control group increased 376% and 751%, respectively, as compared to the normal control group, which indicated that the high-fat-diet-induced hyperlipidemic hamster model was successful.
Effect of compound 22 on LDLR expression in hepatic cells
Mechanisms' studies demonstrated that PCSK9 could bind to the LDL receptor and target it for lysosomal degradation in hepatic cells 3 . Lower PCSK9 may promote LDLR expression and increase LDL-C clearance. Since compound 22 decreases PCSK9 protein expression in HepG2 cells with an IC 50 value of 1.34 mmol/L and PCSK9 mRNA expression with an IC 50 value of 1.10 mmol/L (Supporting Information Figs. S2 and S3), for the purpose of exploring the lipid-lowering mechanism of compound 22, we tested the effect of compound 22 on LDLR expression in HepG2 cells.
HepG2 cells were treated with increasing concentrations of compound 22 (0.1, 0.5, 1, 2.5, and 5 mmol/L) for 24 h. Results demonstrated that compound 22 promotes hepatic cell LDLR expression in a dose-dependent manner with optimal 2.06-fold at 5 mmol/L compared to DMSO ( Fig. 3) , consistent with 2.37-fold LDL-uptake rate in DiI-LDL uptake assay (Table 2) , which suggested that the increase of LDL-uptake in HepG2 cells mainly depended on the promotion of LDLR expression by compound 22.
hERG testing of compound 22
Blockade of the human hERG channel was a significant hurdle encountered in drug discovery. Because compound 22 was efficacious in vivo, it was subjected to hERG testing using a patchclamp experiment. The result showed that the IC 50 value of compound 22 on hERG inhibition was 7.99 mmol/L. Compared to berberine (IC 50 Z 3.1 mmol/L) 24 , compound 22 exhibited lower inhibitory activity on the hERG channel in vitro. 
Conclusions
In this study, a novel series of indole-containing THPBs were designed, synthesized, and evaluated as PCSK9 modulators for the treatment of hyperlipidemia. SAR exploration led to the identification of a highly potent PCSK9 modulator 22 (IC 50 Z 1.34 mmol/L), which promoted 2.37-fold (5 mmol/L) LDL uptake in HepG2 cells. Notably, as a lead compound, compound 22 showed excellent in vivo hypolipidemic potency and a good pharmacokinetic profile, which is much better than berberine. To conclude, results we have earned suggest that compound 22 worths further investigation as an anti-hyperlipidemic agent.
Experimental
General metods of chemistry
Chemicals and solvents were purchased from commercial sources (Alfa, Acros, SigmaeAldrich, and Shanghai Chemical Reagent Company) and used without further purification. Analytical thin layer chromatography (TLC) was HSGF 254 (0.15e0.2 mm thickness, YantaiHuiyou Company, China). Column chromatography was performed with CombiFlash Companion system (Teledyne Isco, Inc. Lincoln, NE, USA). Nuclear magnetic resonance spectra was recorded on a 400 MHz instrument (TMS as IS). Chemical shifts were reported in parts per million (ppm). Proton coupling patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br). Low-and highresolution mass spectra (MS and HR-MS) were given with electrospray ionization (ESI) produced by Q-TOF mass spectrometer. All target compounds were confirmed with over 95% purity (Supporting Information Table S2 ), which were determined by Agilent-1100 HPLC with binary pump, photodiode array detector (DAD), using Agilent Extend-C18 column (15 cm Â 0.46 cm, 5 mm), CH 3 OH/H 2 O [0.1% triethylamine was added in CH 3 OH Z 70/30 (v/v)] or CH 3 OH/H 2 O [0.1% triethylamine was added in CH 3 OH Z 60/40 (v/v)] at 1.0 mL/min, and calculating the peak areas at 280 nm. Berberine was purchased from meilun biotechnology (Dalian, China). Effects of test compounds on PCSK9 expression in HepG2 cells. Test compounds (5 mmol/L) were co-incubated with HepG2 cells for 24 h. Then the cells were collected and lysed in RIPA buffer containing protease inhibitor cocktail. Western blot was utilized to measure PCSK9 expression in HepG2 cells. The abundance of PCSK9 was quantified using imageJ software with normalization by signals of b-actin. Data are presented as mean AE SEM of three independent experiments. * P < 0.05; ** P < 0.01; *** P < 0.001; as compared to the vehicle group.
4.2.
General synthetic procedures for the target compounds 7-28 (compound 7 as example)
To a solution of benzo[d][1,3]dioxole-5-carbaldehyde (29a, 20 mmol) and ammonium acetate (3.08 g, 40 mmol) in nitromethane (20 mL) was added acetic acid (10 mL), and the resulting mixture was heated to 80 C for 4 h. Then the mixture was concentrated, and the concentrate was added saturated NaHCO 3 
Lithium aluminium hydride (2.16 g, 57 mmol) was slowly added into dry tetrahydrofuran (50 mL) to form suspensions. A solution of 30a (3.67 g, 19 mmol) in tetrahydrofuran (50 mL) was added dropwise to suspensions at 0 C, and the mixture was stirred for 4 h at 65 C. The reaction mixture was cooled to room temperature (RT) and diluted with CH 2 Cl 2 (150 mL), and then the reaction mixture was quenched with appropriate ice-water and filtered. The filtrate was evaporated under reduced pressure to get the product (31a) ( 19 .95 mmol), 1-hydroxybenzotriazole (3.23 g, 23.94 mmol), and triethylamine (2.01 g, 19.95 mmol) were dissolved in 50 mL of dichloromethane, and the mixture was stirred for 1 h at room temperature. Then a solution of 2-(benzo[d][1,3]dioxol-5-yl) ethanamine (31a) (13.3 mmol) in dichloromethane (20 mL) was added into the mixture and stirred for 8 h, water was added, the mixture was extracted with ethyl acetate, and the organic extracts were washed with brine, dried over Na 2 SO 4 , and concentrated. The mixture was stirred for 4 h at 90 C. Then the mixture was evaporated under reduced pressure to get the residue. With water added, the mixture was extracted with ethyl acetate, and the organic extracts were washed with brine, dried over Na 2 SO 4 13 Compound 35p was prepared in a similar manner as described for compound 7. 6-(Benzyloxy)-7-methoxy-1-((5-methoxy-1H-indol-3-yl)methyl)-3,4-dihydroisoquinoline (35p, 2 mmol) dissolved in 10 mL of water, and (S,S)-Noyori's catalyst (0.04 mmol), AgSbF 6 (0.06 mmol), La(OTf) 3 (0.6 mmol), CTAB (2 mmol) and HCOONa (3 mmol) were added. The solution was heated to 40 C under for 12 h. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, and the combined organic phase was evaporated under reduced pressure to get the crude product, which was purified by flash chromatography on silica gel to get (R)-35p (441 g, 1.03 mmol, 51%). (R)-35p (428.5 mg, 1 mmol) was dissolved in 20 mL of acetonitrile, then excess of formaldehyde and 0.5 mL of formic acid were added into solution. The mixture was stirred for 2 h at 80 C. The pH of the mixture was adjusted to alkalinity with the addition of saturated NaHCO 3 . The organic layer was separated and washed with water. The combined organic phase was evaporated under reduced pressure and then chromatographed on silica gel to give the target product (R)- 22 (197 
Pharmacokinetic profiles in male hamsters
Compound 22 was subjected to PK studies on male hamsters (n Z 3, each group). Hamsters in oral administration group were given 20 mg/kg test compound (0.5% carboxymethylcellulose sodium) by oral gavage. Hamsters in intravenous administration group were given 10 mg/kg test compound (5% DMSO, 10% cremophor EL in 85% saline) by intravenous administration. Blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h after oral or intravenous administration. Serum samples were isolated by centrifuging for 10 min at 4000Âg. The test compound concentrations in serum were measured by LC/MS/ MS.
In vivo cholesterol-lowering assay
Male Syrian hamsters with body weights of 100e120 g were purchased from Beijing Vital River Laboratory Animal Technology and housed under controlled temperature (22AE2 C) and lighting (12 h light/dark cycle). All hamsters had free access to food and water. After 7 days of acclimatization, hamsters were divided into normal control group (n Z 7) and HFD group (n Z 21). Then the HFD group was switched into a high-fat diet (0.5% cholesterol; Research Diets, Inc. New Brunswick, NJ, USA) to induce hyperlipidemia. One week later, hamsters of the HFD group were divided into HFD control group and test groups randomly (n Z 7 per group). Test groups were given a daily dose test compound 22 30 mg/kg or fenofibrate 100 mg/kg by oral gavage for 21 days. The control groups were given a vehicle (0.5% carboxymethylcellulose sodium). At the end of the animal experiment, blood samples were collected from all the hamsters under anesthesia after 15 h of fasting (5 p.m.e8 a.m.). Serum was isolated by centrifuging for 10 min at 4000Âg, and TC and LDL-C levels were measured using commercially available kits purchased from Maccura Biotechnology (Guangzhou, China).
The study was conducted in accordance with guidelines and ethics of Institutional Animal Care and Use Committee (IACUC), Shanghai Institute of Materia Medica, Chinese Academy of Sciences and the Ethics Committee of Shanghai Xuhui Central Hospital (China).
hERG testing using FluxORä thallium assay
Step 1: Growing cells. CHO-hERG-ZG cells are grown in 75 cm 2 flask with complete medium with 100 mg/mL G418 and 100 mg/mL hygromycin B until 80%e90% confluency. Wash cells with PBS once. Incubate cells with 1 mL 0.25% trypsin until all cells are rounded and can be easily dislodged from the surface. Add 10 mL complete medium to stop trypsin activity. Disassociate cells by thoroughly and repetitively pipetting. Transfer them to 50 mL Falcon tube and spin down at 1000 rpm (Labofuge 400 Centrifuge, Thermo Fisher, Germany) for 5 min. Aspirate medium and resuspend cells using a small volume of complete medium, like 0.5 mL. Count cell density.
Step 2: Cell seeding. CHO-hERG-ZG cells are plated into 96-well plates and after plating, tap plates on sides to separate cells and let plates sit in the dark at RT for 30 min before incubation at 37 C for 16-18 h. Cells will reach 80% confluence. After overnight incubation, the media of cells are changed in loading buffer (old media is tapped out) and incubated in the dark at RT for 90 min. Remove the loading buffer and replace with assay buffer. Compounds were added to the cell plate. The cell plate is incubated with compound 22 for 20 min in the dark at RT. Load the cell plates on Functional Drug Screening System (FDSS). Fluorescent signals will be recorded every 2 s till 10 s. At 10 s, stimulus buffer will be added to cells. Then fluorescent signals will be recorded every second till 180 s on FDSS.
Real-time PCR
HepG2 cells were treated with the test compound in the presence of 2% LPDS for 24 h. The total RNA was isolated by Trizol (Invitrogen, cat. 10296010, Leawood, KA, USA) and reversetranscribed to cDNA by reverse transcriptase (Promega, cat. M1705, Madison, USA). The expression of PCSK9 mRNA was assessed by real-time PCR using specific primers and SYBRâ Green Supermix (Bio-Rad, cat. 1725124, Hercules, CA, USA). Primer sequences of PCSK9 gene are 5 0 -CCAAGCCTCTTCT-TACTTCACC-3 0 and 5 0 -GCATCGTTCTGCCATCACT-3 0 .
Statistical analysis
Data were analyzed with GraphPad Prism software. Results are presented as mean AE SEM. Nonlinear regression analysis was used to generate the doseeresponse curve and calculate a concentration of 50% inhibition (IC 50 ) value. Differences between treatment groups were assessed by Student's t-test or one-way analysis of variance (ANOVA). P < 0.05 was considered statistically significant.
